Zacks Investment Research Upgrades Kura Oncology, Inc. (KURA) to Buy
Zacks Investment Research upgraded shares of Kura Oncology, Inc. (NASDAQ:KURA) from a hold rating to a buy rating in a report issued on Tuesday. Zacks Investment Research currently has $7.75 target price on the stock.
According to Zacks, “Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. “
Several other equities research analysts have also recently commented on the company. Cann reissued a buy rating and issued a $16.00 price target on shares of Kura Oncology in a research note on Monday, May 15th. Oppenheimer Holdings, Inc. set a $16.00 price target on Kura Oncology and gave the company a buy rating in a research note on Wednesday, June 14th. Citigroup Inc. set a $13.00 price target on Kura Oncology and gave the company a buy rating in a research note on Tuesday, August 8th. Finally, Leerink Swann reissued an outperform rating and issued a $18.00 price target (up previously from $16.00) on shares of Kura Oncology in a research note on Thursday, August 10th. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus price target of $14.15.
Kura Oncology (NASDAQ:KURA) opened at 7.10 on Tuesday. The company has a 50-day moving average of $8.14 and a 200 day moving average of $8.67. Kura Oncology has a 12-month low of $4.00 and a 12-month high of $12.10. The stock’s market cap is $141.91 million.
Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Monday, August 7th. The company reported ($0.40) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.43) by $0.03. Equities analysts anticipate that Kura Oncology will post ($1.60) earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “Zacks Investment Research Upgrades Kura Oncology, Inc. (KURA) to Buy” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://www.thecerbatgem.com/2017/09/02/zacks-investment-research-upgrades-kura-oncology-inc-kura-to-buy.html.
Several large investors have recently made changes to their positions in the stock. Morgan Stanley raised its stake in Kura Oncology by 175.5% in the first quarter. Morgan Stanley now owns 430,428 shares of the company’s stock valued at $3,788,000 after buying an additional 274,166 shares during the period. State Street Corp bought a new stake in Kura Oncology during the second quarter valued at $1,394,000. Northern Trust Corp raised its stake in Kura Oncology by 939.3% in the second quarter. Northern Trust Corp now owns 147,483 shares of the company’s stock valued at $1,372,000 after buying an additional 133,293 shares during the period. Alethea Capital Management LLC raised its stake in Kura Oncology by 128.1% in the second quarter. Alethea Capital Management LLC now owns 193,346 shares of the company’s stock valued at $1,798,000 after buying an additional 108,577 shares during the period. Finally, Goldman Sachs Group Inc. bought a new stake in Kura Oncology during the first quarter valued at $533,000. 39.07% of the stock is owned by institutional investors and hedge funds.
About Kura Oncology
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related stocks with our FREE daily email newsletter.